- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05743777
PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
A Phase II Study of PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is being done to answer the following question: Can the addition of a new treatment improve the cancer-shrinking ability of the usual treatment in patients with advanced head and neck cancer?
This study is being done in order to find out if this approach is better or worse than the usual approach for advanced head and neck cancer. The usual approach is defined as the care most people get for advanced head and neck cancer.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically or cytologically-confirmed R/M HNSCC considered incurable by local therapies.
- Patients must not have had any prior systemic therapy administered in the recurrent or metastatic setting.
- Patients with prior systemic therapy given as part of multimodal treatment for locoregionally advanced disease must have completed treatment > 6 months prior to signing consent.
- Patients must have one of the following primary tumor locations: oropharynx, oral cavity, hypopharynx, and larynx. Primary tumor site of nasopharynx (any histology) is excluded.
- Patients with oropharyngeal cancer, must have Human Papilloma Virus (HPV) status determined by p16 immunohistochemical staining on a tumor specimen. Local testing is acceptable.
- Patients must be at least 18 years of age on day of signing informed consent.
- Patients must have measurable disease based on RECIST 1.1 as determined by the site. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- Patients must have an ECOG performance status of 0 or 1
- Abs neutrophil count ≥1,500/μL; Platelets ≥ 100,000; Hemoglobin ≥9 g/dL; Creatinine or measured or calculated creatinine clearance ≤ 1.5 x UNL or ≥ 30mL/min for subject with creatinine levels > 1.5 x UNL; Total bilirubin ≤ 1.5 x UNL or Direct bilirubin ≤ UNL for subjects with total bilirubin levels > 1.5 x ULN; ALT ≤ 2.5 UNL or ≤ 5 x UNL for subjects with liver metastases
- Patients must have PD-L1 positive (CPS ≥1) tumor as determined by PD-L1 testing performed at the local laboratory, from a core or excisional biopsy (fine needle aspirate is not adequate).
- Patients must consent to provision of samples of blood, oropharyngeal swab, and stool for correlative marker analysis.
- Patients must consent to the submission of, and investigator must confirm access to and agree to submit within 4 weeks of enrollment, a formalin-fixed, paraffin-embedded tumour (FFPE) tissue block, cores (two 2 mm cores of tumour from the block), or 10-15 freshly cut unstained tumour slides (4 µm thick) for protocol-mandated exploratory assessments.
- Patient must be able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French
- Women of childbearing potential must have a negative blood pregnancy test within 72 hours prior to receiving the first dose of study medication to confirm eligibility as part of the Pre-Study Evaluation
- Women/men of childbearing potential must have agreed to use a highly effective contraceptive method starting with first dose of study therapy through 180 days after the last dose of study therapy
- Patients must be able to swallow oral medications.
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrolment in the trial to document their willingness to participate.
Exclusion Criteria:
- Patients with disease that is suitable for local therapy administered with curative intent.
- Patients with progressive disease (PD) within six (6) months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
- Patients with persisting toxicity related to prior therapy Grade >2 constituting a safety risk based on the investigator's judgement.
- Patients with a history of a gastrointestinal condition or procedure that, in the opinion of the investigator, may affect oral study drug absorption.
- Patients currently participating and receiving study therapy, or that have participated in a study of an investigational agent and received study therapy, or used an investigational device, any of which occurred within 4 weeks of the first dose of treatment.
- Patients with life expectancy of less than 3 months and/or that have rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.
- Patients with diagnosis of immunodeficiency or that are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Corticosteroid use as pre-medication for allergic reactions (e.g. IV contrast) is allowed. The use of physiologic doses of corticosteroids (e.g.: prednisone ≤10 mg/days) is allowed.
- Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 3 years. Other exceptions may be considered with CCTG consultation.
- Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Patients with active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Patients with allogeneic tissue/solid organ transplant.
- Patients with active infection requiring systemic therapy.
- Patients that have had prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent or any other immune compounds.
- Patients with known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). Subjects with well controlled Human Immunodeficiency Virus (HIV) are allowed.
- Patients that have received live vaccine within 30 days of planned start of study therapy. COVID19 vaccination will be allowed and should be recorded as concomitant medication.
- Patients with history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Patients that are pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of trial treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pembrolizumab + MET-4
|
400 mg IV q6 weekly for a maximum of 18 cycles
Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
|
Active Comparator: Pembrolizumab + Placebo
|
400 mg IV q6 weekly for a maximum of 18 cycles
Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective Response Rate per RECIST 1.1 in first line recurrent and/or metastatic (R/M) HNSCC subjects, treated with pembrolizumab in combination with MET-4 or pembrolizumab with placebo.
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 3 years
|
3 years
|
Duration of response
Time Frame: 3 years
|
3 years
|
Progression-free survival as per RECIST 1.1
Time Frame: 3 years
|
3 years
|
Number and severity of adverse events per CTCAE version 5.0
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Anna Spreafico, University Health Network, Princess Margaret Cancer Centre, Toronto ON Canada
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HN12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Head and Neck Squamous Cell Carcinoma
-
Emory UniversityAstex Pharmaceuticals, Inc.RecruitingHead and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingAdvanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell CarcinomaUnited States, Canada
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)SuspendedRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Glenn J. HannaSecura Bio, Inc.Active, not recruitingMetastatic Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Advanced Head and Neck CancerUnited States
-
AstraZenecaRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaUnited States, Spain, Italy, Canada, Korea, Republic of, United Kingdom, Germany, Vietnam, Japan, France, India, Taiwan, Thailand, Malaysia, Turkey, Brazil, Belgium, Poland, Austria, Hungary
-
Tianjin Medical University General HospitalTianjin Medical University Cancer Institute and HospitalNot yet recruitingLocally Advanced Head and Neck Squamous Cell CarcinomaChina
-
Nanfang Hospital, Southern Medical UniversityNot yet recruitingLocally Advanced Head and Neck Squamous Cell Carcinoma
-
European Organisation for Research and Treatment...Merck KGaA, Darmstadt, GermanyRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaFrance, Belgium, Netherlands, Norway, United Kingdom, Ireland, Italy, Slovenia, Germany, Spain
-
Biotech Pharmaceutical Co., Ltd.CompletedLocally Advanced Head and Neck Squamous Cell CarcinomaChina
-
Seoul National University HospitalClinical Research Center for Solid Tumor, KoreaCompletedLocally Advanced Head and Neck Squamous Cell CarcinomaKorea, Republic of
Clinical Trials on Pembrolizumab
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands
-
Michael BoyiadzisMerck Sharp & Dohme LLCCompletedAcute Myeloid LeukemiaUnited States
-
University of UtahMerck Sharp & Dohme LLCTerminatedNeuroendocrine TumorsUnited States
-
The University of Hong KongMerck Sharp & Dohme LLCUnknown